Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Novartis
Chubb
AstraZeneca
Accenture
Boehringer Ingelheim
Federal Trade Commission
McKinsey
Colorcon
Mallinckrodt

Generated: January 23, 2018

DrugPatentWatch Database Preview

Claims for Patent: 7,569,610

« Back to Dashboard

Summary for Patent: 7,569,610
Title:Modified release formulations of a bupropion salt
Abstract:The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Inventor(s): Oberegger; Werner (Mississauga, CA), Maes; Paul (Toronto, CA), Saleh; Mohammad Ashty (Oakville, CA)
Assignee: Biovail Laboratories International SRL (St. Michael, BB)
Application Number:11/751,768
Patent Claims: 1. A method of treating depression, comprising administering an effective amount of bupropion hydrobromide to treat depression to a subject in need thereof.

2. The method according to claim 1, wherein said method is a method of treating cognitive symptoms in depression, bipolar depression, post partum depression, minor depression, lack of energy in depression, or suicidal depression comprising administering an effective amount of bupropion hydrobromide to treat cognitive symptoms in depression, bipolar depression, post partum depression, minor depression, lack of energy in depression, or suicidal depression to a subject in need thereof.

3. The method according to claim 1, wherein said method comprises administration of a once-daily dosage of bupropion hydrobromide.

4. The method according to claim 2, wherein said method comprises administration of a once-daily dosage of bupropion hydrobromide.

5. The method according to according to claim 1, wherein the bupropion hydrobromide has greater stability measured by less degradation products compared to bupropion hydrochloride.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Daiichi Sankyo
US Department of Justice
Johnson and Johnson
Deloitte
QuintilesIMS
Cerilliant
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot